Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¹¼Ò ¿ÜÀ½ºÎ ¾Ï¿¡¼­ ¿µ¿ª ¸²ÇÁÀýÀÇ Ä¡·á Management of Regional Lymph Nodes in Localized Vulvar Carcinoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2008³â 26±Ç 1È£ p.1 ~ 9
Àå¿øÀÏ, ¼Û¿ë»ó, °­¼ø¹ü, ÀÌÈ¿Ç¥, ¿ìÈ«±Õ, ÇϼºÈ¯, ¹ÚÂùÀÏ,
¼Ò¼Ó »ó¼¼Á¤º¸
Àå¿øÀÏ ( Jang Won-Il ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

¼Û¿ë»ó ( Song Yong-Sang ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
°­¼ø¹ü ( Kang Soon-Beom ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
ÀÌÈ¿Ç¥ ( Lee Hyo-Pyo ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç
¿ìÈ«±Õ ( Wu Hong-Gyun ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
ÇϼºÈ¯ ( Ha Sung-Whan ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¹ÚÂùÀÏ ( Park Charn-Il ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñÀû: ¿ÜÀ½ºÎ ¾ÏȯÀÚ¿¡¼­ ±¹¼Ò¿µ¿ª Ä¡·á½ÇÆп¡ ´ëÇÑ ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·áÀÇ ¿µÇâÀ» Æò°¡ÇÏ°í ÀÓ»óÀûÀ¸·Î ¸²ÇÁÀýÀÌ ÀüÀÌ°¡ ¾ø´Â ȯÀڵ鿡¼­ ¼­ÇýºÎ ¸²ÇÁÀý¿¡ ´ëÇÑ Ä¡·á¹æħÀ» °áÁ¤ÇØ º¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1979³â 10¿ùºÎÅÍ 2004³â 6¿ù±îÁö ¼­¿ï´ëÇб³º´¿ø¿¡¼­ ÀÏÂ÷¼º ¿ÜÀ½ºÎ ¾ÏÀ¸·Î Ä¡·á¸¦ ¹ÞÀº ȯÀÚ 66¸í¿¡ ´ëÇØ ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. À̵é Áß¿¡¼­ ¿ø°ÝÀüÀÌ°¡ ÀÖ´Â 2¸í, °í½ÄÀû ¸ñÀûÀ¸·Î Ä¡·á¸¦ ¹ÞÀº 6¸í, ÀÌÀü¿¡ °ñ¹ÝºÎÀ§ ¹æ»ç¼± Ä¡·áÀÇ º´·ÂÀÌ ÀÖ´Â 3¸í, ÃßÀû°üÂûÀÌ Å»¶ôµÈ 4¸í, Àǹ«±â·ÏÀÌ ºÒÃæºÐÇÑ 1¸íÀ» Æ÷ÇÔÇÏ¿© 16¸íÀÇ È¯ÀÚµéÀº À̹ø ºÐ¼®¿¡¼­ Á¦¿ÜµÇ¾ú´Ù. 50 ¸í Áß¿¡ ¼ö¼ú¸¸ ¹ÞÀº ȯÀÚ°¡ 35¸í, ¼ö¼ú°ú ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚ°¡ 10¸í, ¹æ»ç¼± Ä¡ ·á¸¸À» ¹ÞÀº ȯÀÚ°¡ 5¸íÀ̾ú´Ù.

°á°ú: 5³â Àüü »ýÁ¸À²°ú ¹«º´ »ýÁ¸À²Àº °¢°¢ 91%, 78%¿´´Ù. 12¸í(26%)¿¡¼­ Ä¡·á ½ÇÆи¦ º¸¿´À¸¸ç, ±¹¼Ò ½ÇÆа¡ 8¸í, ¿µ¿ª¸²ÇÁÀý ÀüÀÌ°¡ 3¸í, ¿ø°Ý ÀüÀÌ°¡ 1¸íÀ̾ú´Ù. ¼ö¼ú°ú ¹æ»ç¼±Ä¡·á¸¦ °°ÀÌ ¹ÞÀº ȯÀÚµéÀÌ ¼ö¼ú¸¸À» ¹ÞÀº ȯÀڵ麸´Ù À§Çè¿äÀÎÀ» ´õ ¸¹ÀÌ °¡Áö°í ÀÖ¾úÁö¸¸, ¹«º´ »ýÁ¸À²Àº µÎ Áý´Ü¿¡¼­ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù(5³â¹«º´ »ýÁ¸À² 78% vs. 83%, p=0.66). ÀáÀ缺 ¸²ÇÁÀý ÀüÀÌÀÇ ºóµµ´Â 10%¿´´Ù. ÀÓ»óÀûÀ¸·Î ¸²ÇÁÀý ÀüÀÌ°¡ ¾ø¾ú´ø 31¸íÀÇ È¯ÀÚµé Áß¿¡¼­ 10¸íÀº ¼­ÇýºÎ ¸²ÇÁÀý ÀýÁ¦¼úÀ» ¹ÞÁö ¾Ê¾ÒÁö¸¸, À̵é Áß¿¡¼­ ¿µ¿ª¸²ÇÁÀý ÀüÀ̸¦ °æÇèÇÑ »ç¶÷Àº ¾Æ¹«µµ ¾ø¾ú´Ù.

°á·Ð: Ä¡·á½ÇÆÐÀÇ À§Çè¿äÀÎÀ» °¡Áø ¿ÜÀ½ºÎ ¾ÏÀڵ鿡°Ô ¼ö¼ú ÈÄ ¹æ»ç¼± Ä¡·á´Â ÀáÀçÀûÀÎ ÀÌÁ¡À» °¡Áö°í ÀÖ´Ù. ÀÓ»óÀûÀ¸·Î ¸²ÇÁÀý ÀüÀÌ°¡ ¾ø´Â À§Çèµµ°¡ ³·Àº ȯÀڵ鿡°Ô´Â ¼­ÇýºÎ ¸²ÇÁÀý ÀýÁ¦¼úÀ» ÇÏÁö ¾Ê´Â °ÍÀ̳ª ¼­ÇýºÎ ¸²ÇÁÀý¿¡ ´ëÇØ ¿¹¹æÀû ¹æ»ç¼±Ä¡·á¸¦ ÇÏ´Â °Í¿¡ ´ëÇؼ­ °í·ÁÇØ º¼ ¼ö ÀÖ°Ú´Ù.

Purpose: To evaluate the impact of postoperative radiotherapy on loco-regional failure in patients with vulvar carcinoma and to determine the treatment strategy for inguinal lymph nodes.

Materials and Methods: Sixty-six patients who received treatment for primary vulvar carcinoma at Seoul National University Hospital, from October 1979 through June 2004, were retrospectively analyzed. Sixteen patients were excluded from the analysis due to the following reasons: distant metastases in two patients; palliative intent for six patients; previous radiotherapy given to the pelvis in three patients; follow-up loss after surgery for four patient; insufficient medical records for one patient. Of 50 eligible patients, 35 were treated with surgery alone (S), ten were treated with surgery followed by radiotherapy (S+RT), and five were treated with radiotherapy alone.

Results: The 5-year overall survival (OS) and disease-free survival (DFS) rates of all patients were 91% and 78%, respectively. Twelve patients (26%) experienced treatment failures and the sites of initial failure were as follows: a primary site in eight patients; regional lymph nodes in three patients; the lung in one patient. Although risk factors for failure were more common in the S+RT group than the S group of patients (p £¼0.05), the DFS rates were similar for the two groups (5-year DFS rates, 78% vs. 83%, p=0.66). The incidences of occult lymph node metastases was 10%. Ten of 31 patients with clinically negative lymph nodes did not received inguinal lymph node dissection, but no patient experienced regional failure.

Conclusion: Postoperative radiotherapy may have a potential benefit for patients with risk factors for failure. The omission of inguinal dissection or elective radiotherapy to the inguinal lymph nodes may be considered in low-risk patients with clinically negative lymph nodes.

Å°¿öµå

¿ÜÀ½ºÎ¾Ï;¸²ÇÁÀý;¹æ»ç¼±Ä¡·á;¼ö¼ú
Vulvar cancer;Lymph node;Radiotherapy;Surgery

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS